• 1
    Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 204154.
  • 2
    Hong B, Lui VW, Hashiguchi M, Hui EP, Chan AT. Targeting tumor hypoxia in nasopharyngeal carcinoma. Head Neck 2011; doi: 10.1002/hed.21877 [Epub ahead of print].
  • 3
    Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 111824.
  • 4
    Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ. A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer 2000; 89: 2427.
  • 5
    Leung SF, Zee B, Ma BB et al. Plasma Epstein–Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 54148.
  • 6
    Chan AT, Lo YM, Zee B et al. Plasma Epstein–Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 16149.
  • 7
    Lin JC, Chen KY, Wang WY et al. Detection of Epstein–Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol 2001; 19: 260715.
  • 8
    Xu J, Wan XB, Huang XF et al. Serologic antienzyme rate of Epstein–Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. J Clin Oncol 2010; 28: 52029.
  • 9
    Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 266672.
  • 10
    Rubin Grandis J, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 82432.
  • 11
    Wan XB, Fan XJ, Chen MY et al. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 2010; 6: 395404.
  • 12
    Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 56778.
  • 13
    Rodriguez MO, Rivero TC, del Castillo Bahi R et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9: 3439.
  • 14
    Rojo F, Gracias E, Villena N et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010; 16: 247482.
  • 15
    Talavera A, Friemann R, Gomez-Puerta S et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69: 58519.
  • 16
    Yang C, Tang X, Guo X et al. Aurora-B mediated ATM Serine 1403 phosphorylation is required for mitotic ATM activation and the spindle checkpoint. Mol Cell 2011; 44: 597608.
  • 17
    Khan J, Ezan F, Cremet JY et al. Overexpression of active aurora-C kinase results in cell transformation and tumour formation. PLoS ONE 2011; 6: e26512.
  • 18
    Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004; 14: 2936.
  • 19
    Liu Q, Ruderman JV. Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci U S A 2006; 103: 58116.
  • 20
    Marumoto T, Zhang D, Saya H. Aurora-A – a guardian of poles. Nat Rev Cancer 2005; 5: 4250.
  • 21
    Tatsuka M, Sato S, Kitajima S et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 2005; 24: 11227.
  • 22
    Bischoff JR, Anderson L, Zhu Y et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17: 305265.
  • 23
    Zhou H, Kuang J, Zhong L et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20: 18993.
  • 24
    Klein A, Flugel D, Kietzmann T. Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1. Mol Biol Cell 2008; 19: 366775.
  • 25
    Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 206571.
  • 26
    Kao SY, Chen YP, Tu HF et al. Nuclear STK15 expression is associated with aggressive behaviour of oral carcinoma cells in vivo and in vitro. J Pathol 2010; 222: 99109.
  • 27
    Shang X, Burlingame SM, Okcu MF et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009; 8: 24619.
  • 28
    Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008; 14: 445562.
  • 29
    Tanaka E, Hashimoto Y, Ito T et al. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 2007; 13: 133140.
  • 30
    Reiter R, Gais P, Jutting U et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 513641.
  • 31
    Grandis JR. Prognostic biomarkers in head and neck cancer. Clin Cancer Res 2006; 12: 50056.
  • 32
    Guan Z, Wang XR, Zhu XF et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 2007; 67: 1043644.
  • 33
    Wan XB, Long ZJ, Yan M et al. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 2008; 29: 19307.
  • 34
    Huang PY, Mai HQ, Luo DH et al. Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Ai Zheng 2009; 28: 103342.
  • 35
    Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60: 11126.
  • 36
    Hui EP, Chan AT, Pezzella F et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595604.
  • 37
    Wan XB, Fan XJ, Chen MY et al. Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma. Cancer Biol Ther 2009; 8: 15006.
  • 38
    Mancini M, Aluigi M, Leo E et al. Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457. Br J Haematol 2011; 156: 2658.
  • 39
    Huang XF, Luo SK, Xu J et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008; 111: 285465.
  • 40
    Harrington EA, Bebbington D, Moore J et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 2627.
  • 41
    Traynor AM, Hewitt M, Liu G et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2010; 67: 30514.
  • 42
    Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 218.
  • 43
    Ma BB, Kam MK, Leung SF et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012; 23: 128792.
  • 44
    Wang LH, Xiang J, Yan M et al. The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res 2010; 70: 911828.
  • 45
    Lee SL, Rouhi P, Dahl Jensen L et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A 2009; 106: 1948590.
  • 46
    Chan CM, Ma BB, Hui EP et al. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma–a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. Oral Oncol 2007; 43: 3738.
  • 47
    Katayama H, Sasai K, Kawai H et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 5562.